AXSM - Axsome Therapeutics, Inc.

QQQ $ 622.49 $ 0.90 (0.15 %)

DIA $ 479.63 $ 5.34 (1.13 %)

SPY $ 683.37 $ 2.90 (0.43 %)

TLT $ 89.91 $ 0.01 (0.01 %)

GLD $ 380.58 $ -0.09 (-0.02 %)

Previous Close

$ 139.61

Open

$ 137.21

Bid

$ 135.00 x 6

Ask

$ 145.00 x 9

Day's Range

$ 137.00 - $ 142.19

52 Week Range

$ 75.56 - $ 142.19

Volume

551,832

Average Volume

Market Cap

7.04B

Beta (5Y Monthly)

$ 0.55

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-03-2025	09-30-2025	10-Q
2	08-04-2025	06-30-2025	10-Q
3	05-05-2025	03-31-2025	10-Q
4	02-18-2025	12-31-2024	10-K
5	11-12-2024	09-30-2024	10-Q
6	08-05-2024	06-30-2024	10-Q
7	05-06-2024	03-31-2024	10-Q
8	02-23-2024	12-31-2023	10-K
9	11-06-2023	09-30-2023	10-Q
10	08-07-2023	06-30-2023	10-Q
11	05-09-2023	03-31-2023	10-Q
12	02-28-2023	12-31-2022	10-K
13	11-07-2022	09-30-2022	10-Q
14	08-09-2022	06-30-2022	10-Q
15	05-02-2022	03-31-2022	10-Q
16	03-01-2022	12-31-2021	10-K
17	11-08-2021	09-30-2021	10-Q
18	08-09-2021	06-30-2021	10-Q
19	05-10-2021	03-31-2021	10-Q
20	03-01-2021	12-31-2020	10-K
21	11-05-2020	09-30-2020	10-Q
22	08-10-2020	06-30-2020	10-Q
23	05-11-2020	03-31-2020	10-Q
24	03-12-2020	12-31-2019	10-K
25	11-07-2019	09-30-2019	10-Q
26	08-08-2019	06-30-2019	10-Q
27	05-09-2019	03-31-2019	10-Q
28	03-15-2019	12-31-2018	10-K
29	11-09-2018	09-30-2018	10-Q
30	08-08-2018	06-30-2018	10-Q
31	05-08-2018	03-31-2018	10-Q
32	03-07-2018	12-31-2017	10-K
33	11-08-2017	09-30-2017	10-Q
34	08-09-2017	06-30-2017	10-Q
35	05-09-2017	03-31-2017	10-Q
36	03-07-2017	12-31-2016	10-K
37	11-14-2016	09-30-2016	10-Q
38	08-09-2016	06-30-2016	10-Q
39	05-11-2016	03-31-2016	10-Q
40	03-24-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Mizuho Maintains Outperform on Axsome Ther...
11/06/2025 16:47:46

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target f...

Avenue Therapeutics Signs Agreement To Sel...
11/06/2025 12:34:37

Avenue Therapeutics, Inc. (OTC:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on...

Axsome Therapeutics Signs Deal To Acquire ...
11/06/2025 12:12:05

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous syst...

Morgan Stanley Maintains Overweight on Axs...
11/04/2025 17:46:32

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target...

HC Wainwright & Co. Maintains Buy on Axsom...
11/04/2025 17:27:32

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the pri...

RBC Capital Maintains Outperform on Axsome...
11/04/2025 16:26:44

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price targe...

Wells Fargo Maintains Overweight on Axsome...
11/04/2025 16:03:27

Wells Fargo analyst Benjamin Burnett maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and lowers the price targ...

Guggenheim Maintains Buy on Axsome Therape...
11/04/2025 15:39:53

Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $200...

Needham Reiterates Buy on Axsome Therapeut...
11/04/2025 09:23:51

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $154 price target.

Axsome Therapeutics Files For Mixed Shelf;...
11/03/2025 22:29:51

- SEC Filing

Axsome Therapeutics Q3 Adj. EPS $(0.68) Be...
11/03/2025 12:11:47

Axsome Therapeutics Q3 Sales $170.992M Bea...
11/03/2025 12:01:12

Earnings Scheduled For November 3, 2025
11/03/2025 11:11:31

Uncovering Potential: Axsome Therapeutics'...
10/31/2025 18:01:47

Morgan Stanley Maintains Overweight on Axs...
10/20/2025 15:24:09

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target...

B. Riley Securities Initiates Coverage On ...
10/01/2025 14:33:10

B. Riley Securities analyst Madison El-Saadi initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Buy rating and a...

A Glimpse Into The Expert Outlook On Axsom...
09/03/2025 14:00:32

Wells Fargo Assumes Axsome Therapeutics at...
09/03/2025 12:51:46

Wells Fargo analyst Benjamin Burnett assumes Axsome Therapeutics (NASDAQ:AXSM) with a Overweight rating and announces Price ...

tonix-pharmas-drug-gets-fda-nod-for-chronic-pain-condition-first-new-therapy-in-over-15-years

Tonix Pharma's Drug Gets FDA Nod For Chron...
08/18/2025 13:45:18

FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025.

axsome-therapeutics-analysts-increase-their-forecasts-after-q2-earnings

Axsome Therapeutics Analysts Increase Thei...
08/05/2025 17:40:51